Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24
Antunes, L.; Nunes, B.; Nunez, O.; Martinez-Baz, I.; Dockx, Y.; Borg, M.-L.; Oroszi, B.; Duffy, R.; Dürwald, R.; Kuliese, M.; Machado, A.; Petrovic, G.; Lazar, M.; Guiomar, R.; Alvarez Rio, V.; Castilla, J.; Magerman, K.; Dziugyte, A.; Turi, G.; Fitzgerald, M.; Hackmann, C.; Jancoriene, L.; Gomez, V.; Lovric Makaric, Z.; Popovici, O.; Rojas Castro, M. Y.; Rose, A. M. C.; European Hospital Vaccine Effectiveness Group,
Show abstract
IntroductionGenetic changes in COVID-19 variants/sublineages (VSLs) can reduce vaccine effectiveness (VE). Timely VSL-specific VE estimates are essential, but study-specific VSL identification by whole genome sequencing (the "gold standard") is expensive and time-consuming. Alternatively, VSL-specific VE has been estimated from external sequencing data (VSL predominance period by proxy: PP). We propose two novel approaches for use in test-negative design (TND) studies to estimate VSL-specific VE when study-specific VSL identification is not possible. MethodsWe demonstrate the variant category model (VCM) and the variant proportion model (VPM) approaches. Using data from a hospital-based TND study among adults [≥]65 years, during the period of sequential predominance of XBB and BA.2.86 in 2023/24, we estimated the VE as (1-OR) x 100%. For the VCM, we used a binary variable categorising "most likely underlying sublineage" based on publicly available sequencing data. For the VPM, we used a continuous variable with values from 0 to 1 representing the weekly proportion of BA.2.86. We validated results using study-specific VSL identification from sequenced study data (SD) and the standard PP approach. ResultsOverall, at 14-59 days post vaccination, VE point estimates against XBB were within {+/-}3% absolute for the VE estimated using both models, with an equivalent standard PP validation. We could not validate using SD, as there were no vaccinated XBB cases. Against BA.2.86, VE was lower than against XBB, and the VCM and VPM results were within {+/-}7% absolute of each other, with lowest validation results from SD but equivalent results from the PP. ConclusionsBoth proposed approaches produced similar VE estimates to those from well-known methods. The VPM could also provide VE estimates when the validation techniques were limited by low sample size.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study 95%
- MVA-BN Vaccine Effectiveness: A Systematic Review of Real-World Evidence in Outbreak Settings 95%
- Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022 95%
Similar papers in this journal
- COVID-19 vaccine uptake and effectiveness by time since vaccination in the Western Cape province, South Africa: An observational cohort study during 2020-2022 95%
- Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (Covishield™) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021 94%
- Cost-effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the Portuguese elderly population 94%
Similar papers in this journal
- Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis 95%
- Non-pharmaceutical interventions and vaccinating school children required to contain SARS-CoV-2 Delta variant outbreaks in Australia: a modelling analysis 94%
- Potential health and economic impact of paediatric vaccination using next generation influenza vaccines in Kenya: a modelling study 94%
Similar papers in this journal
- Surveillance of COVID-19 vaccine effectiveness – a real-time case-control study in southern Sweden 93%
- Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina 93%
- Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection 93%
Similar papers in this journal
- Attribution of invasive group A streptococcal infections to varicella and respiratory virus circulation, the Netherlands, 2010-2023 94%
- mRNA vaccines effectiveness against COVID-19 hospitalizations and deaths in older adults: a cohort study based on data-linkage of national health registries in Portugal 94%
- Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.